Recursion Pharmaceuticals...

NASDAQ: RXRX · Real-Time Price · USD
5.65
0.01 (0.18%)
At close: Aug 15, 2025, 10:01 AM

Recursion Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
58.84M 44.58M 39.68M 10M
Cost of Revenue
45.24M 42.59M 48.27M 9.1M
Gross Profit
13.6M 1.99M -8.59M 896K
Operating Income
-479M -350.06M -245.73M -182.78M
Interest Income
15.76M 19.12M 6.25M 73K
Pretax Income
-464.79M -332.13M -239.48M -186.48M
Net Income
-463.66M -328.07M -239.42M -178.07M
Selling & General & Admin
178.18M 110.82M 81.6M 57.68M
Research & Development
314.42M 241.23M 155.7M 135.27M
Other Expenses
n/a -699K -162K -178K
Operating Expenses
492.61M 351.35M 237.13M 192.78M
Interest Expense
1.57M 97K 55K 2.95M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
537.84M 394.63M 285.41M 192.78M
Income Tax Expense
-1.13M -4.06M -55K -8.4M
Shares Outstanding (Basic)
274.21M 207.85M 175.54M 170.27M
Shares Outstanding (Diluted)
274.21M 207.85M 175.54M 170.27M
EPS (Basic)
-1.69 -1.58 -1.36 -1.05
EPS (Diluted)
-1.69 -1.58 -1.36 -1.05
EBITDA
-426.72M -299.57M -227.66M -174.42M
EBIT
-463.22M -332.03M -239.42M -183.53M
Depreciation & Amortization
36.49M 24.4M 19.49M 9.1M